Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
A small-molecule hexapeptide-like angiotensin IV analog developed at Washington State University as a preclinical HGF/c-Met-dependent cognition candidate. Not FDA-approved; no human trials.
Lowest Price
$38.00
Highest Price
$180.00
Average Price
$86.00
Potential Savings
99%
across 3 options
0 of 3 vendors are lab-verified for Dihexa
We cross-check each vendor's Certificate of Analysis against the issuing lab's own verification portal — so “cheapest” isn't the only signal.
Best price trend
Lowest $/mg for Dihexa · last 9 days
$6.90/mg
flat
Trust grade first, cheapest within grade
vial · 150mgmoglabs.bio· price updated today
Lot DIH001· tested 2026-03-23
$0.253/mg
vial · 5mgamc-essentials.com· price updated today
$8.00/mg
97% more per mg
vial · 10mggeneticpeptide.com· price updated today
$279.00−35%
$180.00$18.00/mg
99% more per mg
Prices are estimates and may vary. For research use only. We may earn a commission on purchases through affiliate links. Not medical advice.
Check formulation: Lyophilized powder requires reconstitution before use. Pre-mixed solutions are more convenient but may have a shorter shelf life and higher prices.
Compare per-mg cost: Different strengths and quantities make direct price comparison difficult. Calculate the per-milligram cost to find the true best value.
Verify COAs: Look for vendors that publish per-batch Certificates of Analysis from named, accredited labs. Every vendor on this page is verified for endotoxin testing — not just HPLC purity.
McCoy et al. (J Pharmacol Exp Ther 2013, PMID 23055539) is the original dihexa characterization: oral dihexa reversed scopolamine-induced memory deficits and improved Morris water maze performance in aged rats at low doses. Sun et al. (Brain Sci 2021, PMID 34827486) reported that dihexa rescued cognitive impairment in the APP/PS1 Alzheimer's mouse via PI3K/AKT signaling, with increased synaptophysin and reduced neuroinflammation. Wright & Harding (J Alzheimers Dis 2015, PMID 25649658) reviewed the brain HGF/c-Met system as an Alzheimer's target. Note: Benoist et al. (JPET 2014, PMID 25187433), which reported the HGF/c-Met-dependent synaptogenesis mechanism, was retracted in 2025 and should not be relied on as primary evidence. The 'roughly seven orders of magnitude more potent than BDNF' descriptor refers to in vitro dendritic spine EC50 values, not clinical efficacy. Dihexa has never entered human clinical trials; Athira Pharma's related analog fosgonimeton failed its Phase 2/3 LIFT-AD Alzheimer's endpoint in 2024 and was discontinued, after which Athira shifted focus to ATH-1105 for ALS.
This platform provides informational tools only, not medical advice.
Evaluation of metabolically stabilized angiotensin IV analogs as procognitive/antidementia agents (McCoy et al., J Pharmacol Exp Ther, PMID 23055539)
2013
The Brain Hepatocyte Growth Factor/c-Met Receptor System: A New Target for the Treatment of Alzheimer's Disease (Wright & Harding, J Alzheimers Dis, PMID 25649658)
2015
AngIV-Analog Dihexa Rescues Cognitive Impairment and Recovers Memory in the APP/PS1 Mouse via the PI3K/AKT Signaling Pathway (Sun et al., Brain Sci, PMID 34827486)
Prices verified as of June 2026. Actual prices may vary. For research use only.
2021
Disclosed Labs